Welcome to Shifa Dental Clinic. We are a specialized dental practice and clinical research institute dedicated to the next frontier of oral healthcare: natural tooth regeneration.
For decades, the only answer to tooth loss has been artificial replacements like dentures, bridges, and titanium implants. At Shifa Dental Clinic, we are working to change that.
We are actively laying the groundwork to participate in global clinical trials for Anti-USAG-1 monoclonal antibody therapies (TRG035). Originally discovered by Dr. Katsu Takahashi and his team at Kyoto University, this breakthrough treatment is designed to stimulate dormant tooth buds, prompting the human body to grow a "third set" of natural teeth.
Most humans have dormant tooth buds that never develop into full teeth due to a specific growth-inhibiting protein called USAG-1. Through advanced neutralizing antibodies (TRG035), this protein is temporarily blocked. Once the inhibitor is removed, the body's natural signaling pathways are reactivated, allowing a brand new, fully functional tooth to develop and erupt naturally from the jawbone.
The TRG035 therapy is currently undergoing rigorous human clinical trials, starting with congenital tooth agenesis (patients born missing permanent teeth) and eventually expanding to acquired tooth loss (teeth lost to decay or injury).
Shifa Dental Clinic is currently building a Patient Registry for future clinical trial cohorts.
Congenital Edentulism: Register your interest if you or your child were born missing multiple teeth.
Acquired Tooth Loss: Join our waitlist for secondary trial phases targeting standard tooth loss.